OMV Surface Engineering Services for Precision CAR-T Homing & Synapse

Online Inquiry

Background Service Service Packages Workflow Highlights FAQs Contact

Despite the transformative potential of CAR-T therapy, solid tumor applications remain hindered by poor T-cell infiltration, antigen heterogeneity, and a highly suppressive tumor microenvironment. Creative Biolabs' OMV Surface Engineering for Precision CAR-T Homing & Synapse platform addresses these barriers by leveraging programmable outer membrane vesicles to transform "cold" tumors into highly visible targets. We provide modular engineering services utilizing SpyTag/SpyCatcher technology and dual-responsive gating to create vesicles that precisely guide CAR-T cells and remodel the tumor-immune interface. This approach enhances tumor-specific homing and synapse formation, enabling you to overcome the immunosuppressive TME and advance your next-generation immunotherapies with greater precision and efficacy.

Introduction

Outer membrane vesicle (OMV) surface engineering is a bio-inspired nanotechnology platform that leverages genetically programmable bacterial vesicles to display multifunctional ligands on their surface, serving as modular carriers for targeted therapeutic delivery. By incorporating tumor-specific recognition elements and immunological synapse-stabilizing molecules, engineered OMV platforms facilitate precise CAR-T homing to solid tumor microenvironments while enhancing the formation of stable and functional immune synapses, ultimately improving cytotoxic efficiency and mitigating off-target recognition.

Fig.1 Precision engineering of OMV surfaces to control CAR-T homing and synaptic stability. (Creative Biolabs Original) Fig.1 Leveraging OMV surface engineering to enhance CAR-T homing and synapse formation.

OMV Surface Engineering for Precision CAR-T Homing & Synapse at Creative Biolabs

Creative Biolabs offers a comprehensive modular platform engineered to functionally bridge CAR-T lymphocytes with solid tumor microenvironments. By utilizing advanced OMVs as dual-functional intermediaries, we empower your program to target and eliminate heterogeneous tumor populations that evade conventional CAR recognition. Our deliverable portfolio includes fully characterized, surface-engineered OMVs alongside the corresponding genetic constructs, all customizable to your specific oncological targets.

Service Packages

Modular OMV Surface Display via SpyTag/SpyCatcher for CAR-T Targeting

This page details our proprietary technology platform for the rapid and site-specific functionalization of OMVs. By leveraging the irreversible isopeptide bond formation between SpyTag and SpyCatcher, we enable the modular decoration of the OMV surface with a variety of targeting ligands or tumor antigens. This plug-and-play system allows for the high-throughput screening of homing signals and the creation of customized OMV populations designed to precisely redirect or capture specific CAR-T cell subsets.

Learn More →

Construction of Bispecific Vesicles for Artificial CAR-T Immunological Synapse

This section focuses on the engineering of synthetic vesicles designed to function as artificial antigen-presenting platforms. We describe the co-display of both a tumor-targeting moiety and a co-stimulatory ligand on a single OMV. This bispecific architecture mimics the natural antigen-presenting cell to construct a controlled, artificial immunological synapse, providing a powerful tool for studying CAR-T activation thresholds, delivering synergistic signals to enhance T-cell proliferation, or priming CAR-T cells ex vivo with superior functionality.

Learn More →

Validation of OMV-to-Tumor Binding Kinetics for CAR-T Guidance

This page presents our comprehensive biophysical characterization of the interaction between engineered OMVs and their target tumor cells. Using techniques, we quantify the affinity, avidity, and binding kinetics of our functionalized vesicles. These critical parameters serve as a predictive guide for subsequent in vitro and in vivo CAR-T homing studies, ensuring that only OMV formulations with optimal binding profiles are advanced to guide CAR-T cells to solid tumors.

Learn More →

Our Service Process

Required Starting Materials:

The sequence or specific clone of the CAR-T target antigen.
The desired targeting antibody/ligand.
Baseline TME profile data.

Key Steps:

Workflow of OMV surface engineering for precision CAR-T homing & synapse at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables: You will receive a complete characterization report, functional validation data, and the purified, engineered OMV batches.

Key Advantages

Antigen-Agnostic Targeting: It enables CAR-T cells to eliminate tumor cells independently of their native antigen expression by artificially tagging the tumor surface.
Overcoming Antigen Heterogeneity: It mitigates a primary barrier in solid tumor therapy by allowing CAR-T cells to recognize and kill tumor cells that lack the targeted antigen.
Reversal of Immune Checkpoint Suppression: It protects CAR-T cells from exhaustion by utilizing engineered OMVs to absorb or block PD-L1 signals within the tumor microenvironment.
Enhanced Tumor Infiltration: It leverages the natural tumor-homing properties of OMVs to improve the physical trafficking and accumulation of CAR-T cells into solid tumor masses.

FAQs

Q1: Does the OMV itself trigger a cytokine storm?

A1: No. The formulation employs an advanced acid-responsive coating that effectively masks the immunogenic bacterial lipids during circulation in the bloodstream. This protective layer ensures that the OMV's adjuvant activity is spatially restricted, initiating its potent immune-stimulating functions only upon reaching the acidic TME.

Q2: Can we use this for any CAR-T target?

A2: Yes. The core of this technology lies in its modular architecture. The surface display system is fully decoupled from the target antigen; it functions as a universal carrier. To redirect specificity, one simply exchanges the targeting ligand or scFv, making the platform adaptable to virtually any predefined tumor-associated antigen without requiring complex re-engineering of the OMV backbone.

Why Choose Us

We uniquely merge synthetic biology with deep immunological insight to transform the OMV from a simple carrier into a programmable navigator for your CAR-T cells. Our platform is engineered for precision, offering superior tumor homing and unmatched modularity that accelerates your path from target discovery to validated therapy.

How to contact us?

Creative Biolabs offers a state-of-the-art OMV surface engineering platform that integrates high-resolution analysis with a programmable dual-locking mechanism for targeted therapeutic delivery. By leveraging advanced bioengineering strategies, we address the key limitations in CAR-T therapy for solid tumors, namely tumor heterogeneity, T-cell exhaustion, and on-target off-tumor toxicity. For further discussion or to request a customized project proposal, please contact our team.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.